Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Nov;85(10):1425–1431. doi: 10.1054/bjoc.2001.2130

Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas

L Loni 1, M Del Tacca 1, R Danesi 1
PMCID: PMC2363952  PMID: 11720423

Abstract

The variability of tumour responses to chemotherapeutic agents is a topic of major interest in current oncology research. Advances in the knowledge of molecular pathology of cancer make available strategies by which tumour cells can be profiled for their genetic background in order to select anticancer agents that might selectively kill cells in a molecular context that matches the mechanism of action of drugs. The next generation of anticancer treatments might thus be tailored on the basis of the numerous molecular alterations identified in tumour cells of a particular patient. However, to exploit these alterations, it is necessary to understand how they influence the cellular pathways that control the sensitivity or, conversely, resistance to chemotherapeutic agents. The aim of this article is to outline major genetic abnormalities in non-Hodgkin lymphomas that can be used to streamline anticancer drug selection and to underscore the major role of pharmacogenetics, which studies the interactions between genetic background and drug activity, to the prediction of likelihood of response and identification of potential new targets for pharmacological intervention. © 2001 Cancer Research Campaign  http://www.bjcancer.com

Keywords: pharmacogenetics, chemosensitivity, drug resistance, non-Hodgkin lymphomas

Full Text

The Full Text of this article is available as a PDF (80.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Katib A. M., Smith M. R., Kamanda W. S., Pettit G. R., Hamdan M., Mohamed A. N., Chelladurai B., Mohammad R. M. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res. 1998 May;4(5):1305–1314. [PubMed] [Google Scholar]
  2. Bellosillo B., Villamor N., Colomer D., Pons G., Montserrat E., Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 1999 Oct 15;94(8):2836–2843. [PubMed] [Google Scholar]
  3. Byrd J. C., Grever M. R., Waselenko J. K., Willis C. R., Park K., Goodrich A., Lucas M. A., Shinn C., Flinn I. W. Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. Semin Oncol. 2000 Apr;27(2 Suppl 5):37–40. [PubMed] [Google Scholar]
  4. Cinatl J., Jr, Kotchetkov R., Gröschel B., Cinatl J., Driever P. H., Kabickova H., Kornhuber B., Schwabe D., Doerr H. W. Azidothymidine resistance of H9 human T-cell lymphoma cells is associated with decreased sensitivity to antitumor agents and inhibition of apoptosis. Int J Mol Med. 1998 Dec;2(6):685–691. doi: 10.3892/ijmm.2.6.685. [DOI] [PubMed] [Google Scholar]
  5. Dolan M. E., McRae B. L., Ferries-Rowe E., Belanich M., van Seventer G. A., Guitart J., Pezen D., Kuzel T. M., Yarosh D. B. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res. 1999 Aug;5(8):2059–2064. [PubMed] [Google Scholar]
  6. Dumontet C., Fabianowska-Majewska K., Mantincic D., Callet Bauchu E., Tigaud I., Gandhi V., Lepoivre M., Peters G. J., Rolland M. O., Wyczechowska D. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999 Jul;106(1):78–85. doi: 10.1046/j.1365-2141.1999.01509.x. [DOI] [PubMed] [Google Scholar]
  7. Döhner H., Fischer K., Bentz M., Hansen K., Benner A., Cabot G., Diehl D., Schlenk R., Coy J., Stilgenbauer S. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995 Mar 15;85(6):1580–1589. [PubMed] [Google Scholar]
  8. Fan S., Cherney B., Reinhold W., Rucker K., O'Connor P. M. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res. 1998 Apr;4(4):1047–1054. [PubMed] [Google Scholar]
  9. Fan S., el-Deiry W. S., Bae I., Freeman J., Jondle D., Bhatia K., Fornace A. J., Jr, Magrath I., Kohn K. W., O'Connor P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 1994 Nov 15;54(22):5824–5830. [PubMed] [Google Scholar]
  10. Feng L., Achanta G., Pelicano H., Zhang W., Plunkett W., Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med. 2000 Jun;5(6):597–604. doi: 10.3892/ijmm.5.6.597. [DOI] [PubMed] [Google Scholar]
  11. Fisher R. I. Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma. Semin Oncol. 2000 Dec;27(6 Suppl 12):2–8. [PubMed] [Google Scholar]
  12. Frank D. A. STAT signaling in the pathogenesis and treatment of cancer. Mol Med. 1999 Jul;5(7):432–456. [PMC free article] [PubMed] [Google Scholar]
  13. Fujimori A., Harker W. G., Kohlhagen G., Hoki Y., Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 1995 Mar 15;55(6):1339–1346. [PubMed] [Google Scholar]
  14. Gottardi D., De Leo A. M., Alfarano A., Stacchini A., Circosta P., Gregoretti M. G., Bergui L., Aragno M., Caligaris-Cappio F. Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations. Br J Haematol. 1997 Oct;99(1):147–157. doi: 10.1046/j.1365-2141.1997.3353152.x. [DOI] [PubMed] [Google Scholar]
  15. Groves F. D., Linet M. S., Travis L. B., Devesa S. S. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000 Aug 2;92(15):1240–1251. doi: 10.1093/jnci/92.15.1240. [DOI] [PubMed] [Google Scholar]
  16. Haldar S., Basu A., Croce C. M. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997 Jan 15;57(2):229–233. [PubMed] [Google Scholar]
  17. Han S. S., Chung S. T., Robertson D. A., Ranjan D., Bondada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol. 1999 Nov;93(2):152–161. doi: 10.1006/clim.1999.4769. [DOI] [PubMed] [Google Scholar]
  18. Harvey S., Decker R., Dai Y., Schaefer G., Tang L., Kramer L., Dent P., Grant S. Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin Cancer Res. 2001 Feb;7(2):320–330. [PubMed] [Google Scholar]
  19. Hirose M., Kuroda Y. p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines. Cancer Lett. 1998 Jul 17;129(2):165–171. doi: 10.1016/s0304-3835(98)00096-2. [DOI] [PubMed] [Google Scholar]
  20. Johnston J. B., Daeninck P., Verburg L., Lee K., Williams G., Israels L. G., Mowat M. R., Begleiter A. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 1997 Aug;26(5-6):435–449. doi: 10.3109/10428199709050881. [DOI] [PubMed] [Google Scholar]
  21. Kitada S., Andersen J., Akar S., Zapata J. M., Takayama S., Krajewski S., Wang H. G., Zhang X., Bullrich F., Croce C. M. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998 May 1;91(9):3379–3389. [PubMed] [Google Scholar]
  22. Kitada S., Zapata J. M., Andreeff M., Reed J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 2000 Jul 15;96(2):393–397. [PubMed] [Google Scholar]
  23. Kobzdej M., Matuszyk J., Zioło E., Strzadała L. Changes in glucocorticoid-induced apoptosis and in expression of Bcl-2 protein during long-term culture of thymic lymphoma. Arch Immunol Ther Exp (Warsz) 2000;48(1):43–46. [PubMed] [Google Scholar]
  24. Lum B. L., Kaubisch S., Fisher G. A., Brown B. W., Sikic B. I. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother Pharmacol. 2000;45(4):305–311. doi: 10.1007/s002800050045. [DOI] [PubMed] [Google Scholar]
  25. Ma Z., Cools J., Marynen P., Cui X., Siebert R., Gesk S., Schlegelberger B., Peeters B., De Wolf-Peeters C., Wlodarska I. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood. 2000 Mar 15;95(6):2144–2149. [PubMed] [Google Scholar]
  26. Meguerian-Bedoyan Z., Lamant L., Hopfner C., Pulford K., Chittal S., Delsol G. Anaplastic large cell lymphoma of maternal origin involving the placenta: case report and literature survey. Am J Surg Pathol. 1997 Oct;21(10):1236–1241. doi: 10.1097/00000478-199710000-00016. [DOI] [PubMed] [Google Scholar]
  27. Michelutti A., Michieli M., Damiani D., Melli C., Ermacora A., Grimaz S., Candoni A., Russo D., Fanin R., Baccarani M. Effect of fludarabine and arabinosylcytosine on multidrug resistant cells. Haematologica. 1997 Mar-Apr;82(2):143–147. [PubMed] [Google Scholar]
  28. Minn A. J., Rudin C. M., Boise L. H., Thompson C. B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 1995 Sep 1;86(5):1903–1910. [PubMed] [Google Scholar]
  29. Muller C., Christodoulopoulos G., Salles B., Panasci L. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood. 1998 Oct 1;92(7):2213–2219. [PubMed] [Google Scholar]
  30. Muthukkumar S., Ramesh T. M., Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995 Aug 15;60(3):264–270. doi: 10.1097/00007890-199508000-00010. [DOI] [PubMed] [Google Scholar]
  31. Navaratnam S., Williams G. J., Rubinger M., Pettigrew N. M., Mowat M. R., Begleiter A., Johnston J. B. Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas. Leuk Lymphoma. 1998 Mar;29(1-2):139–144. doi: 10.3109/10428199809058389. [DOI] [PubMed] [Google Scholar]
  32. O'Connor P. M., Wassermann K., Sarang M., Magrath I., Bohr V. A., Kohn K. W. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res. 1991 Dec 15;51(24):6550–6557. [PubMed] [Google Scholar]
  33. Pepper C., Thomas A., Hidalgo de Quintana J., Davies S., Hoy T., Bentley P. Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation. Leuk Res. 1999 Nov;23(11):1007–1014. doi: 10.1016/s0145-2126(99)00122-8. [DOI] [PubMed] [Google Scholar]
  34. Reed J. C., Kitada S., Takayama S., Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 1994;5 (Suppl 1):61–65. doi: 10.1093/annonc/5.suppl_1.s61. [DOI] [PubMed] [Google Scholar]
  35. Ribrag V., Massade L., Faussat A. M., Dreyfus F., Bayle C., Gouyette A., Marie J. P. Drug resistance mechanisms in chronic lymphocytic leukemia. Leukemia. 1996 Dec;10(12):1944–1949. [PubMed] [Google Scholar]
  36. Rowley M., Liu P., Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood. 2000 Nov 1;96(9):3175–3180. [PubMed] [Google Scholar]
  37. Schmitt C. A., McCurrach M. E., de Stanchina E., Wallace-Brodeur R. R., Lowe S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999 Oct 15;13(20):2670–2677. doi: 10.1101/gad.13.20.2670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Schmitt E., Steyaert A., Cimoli G., Bertrand R. Bax-alpha promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells. Cell Death Differ. 1998 Jun;5(6):506–516. doi: 10.1038/sj.cdd.4400376. [DOI] [PubMed] [Google Scholar]
  39. Schröder J. K., Kirch C., Flasshove M., Kalweit H., Seidelmann M., Hilger R., Seeber S., Schütte J. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia. 1996 Dec;10(12):1919–1924. [PubMed] [Google Scholar]
  40. Silber R., Degar B., Costin D., Newcomb E. W., Mani M., Rosenberg C. R., Morse L., Drygas J. C., Canellakis Z. N., Potmesil M. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood. 1994 Nov 15;84(10):3440–3446. [PubMed] [Google Scholar]
  41. Simonian P. L., Grillot D. A., Nuñez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 1997 Aug 1;90(3):1208–1216. [PubMed] [Google Scholar]
  42. Sundaresan A., Claypool K., Mehta K., Lopez-Berestein G., Cabanillas F., Ford R. J., Jr Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ. 1997 Oct;8(10):1071–1082. [PubMed] [Google Scholar]
  43. Taylor S. T., Hickman J. A., Dive C. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst. 2000 Jan 5;92(1):18–23. doi: 10.1093/jnci/92.1.18. [DOI] [PubMed] [Google Scholar]
  44. Tu Y., Xu F. H., Liu J., Vescio R., Berenson J., Fady C., Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood. 1996 Sep 1;88(5):1805–1812. [PubMed] [Google Scholar]
  45. Valkov N. I., Sullivan D. M. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol. 1997 Oct;34(4 Suppl 5):48–62. [PubMed] [Google Scholar]
  46. Vose J. M., Link B. K., Grossbard M. L., Czuczman M., Grillo-Lopez A., Gilman P., Lowe A., Kunkel L. A., Fisher R. I. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001 Jan 15;19(2):389–397. doi: 10.1200/JCO.2001.19.2.389. [DOI] [PubMed] [Google Scholar]
  47. Walton M. I., Whysong D., O'Connor P. M., Hockenbery D., Korsmeyer S. J., Kohn K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 1993 Apr 15;53(8):1853–1861. [PubMed] [Google Scholar]
  48. Webb M., Brun M., McNiven M., Le Couteur D., Craft P. MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol. 1998 Aug;102(3):710–717. doi: 10.1046/j.1365-2141.1998.00822.x. [DOI] [PubMed] [Google Scholar]
  49. Wilson W. H., Sorbara L., Figg W. D., Mont E. K., Sausville E., Warren K. E., Balis F. M., Bauer K., Raffeld M., Senderowicz A. M. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. Clin Cancer Res. 2000 Feb;6(2):415–421. [PubMed] [Google Scholar]
  50. Wong S. J., Myette M. S., Wereley J. P., Chitambar C. R. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clin Cancer Res. 1999 Feb;5(2):439–443. [PubMed] [Google Scholar]
  51. Zaja F., Di Loreto C., Amoroso V., Salmaso F., Russo D., Silvestri F., Fanin R., Damiani D., Infanti L., Mariuzzi L. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. Leuk Lymphoma. 1998 Feb;28(5-6):567–572. doi: 10.3109/10428199809058365. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES